Peregrine Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Peregrine Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-168,790	Closed	-$36.3M	–	353
2021 Q1	$36.3M	Buy	168,790 +12,168	+8%	+$2.67M	0.67%	26
2020 Q4	$37M	Buy	156,622 +19,742	+14%	+$4.53M	0.7%	28
2020 Q3	$37.2M	Buy	136,880 +896	+0.7%	+$247K	0.99%	16
2020 Q2	$39.5M	Buy	135,984 +4,311	+3%	+$1.17M	1.12%	10
2020 Q1	$31.3M	Buy	131,673 +1,032	+0.8%	+$237K	1.12%	6
2019 Q4	$28.6M	Buy	130,641 +498	+0.4%	+$101K	0.73%	30
2019 Q3	$22M	Buy	130,143 +17,324	+15%	+$3.06M	0.6%	52
2019 Q2	$20.7M	Hold	112,819	–	–	0.51%	72
2019 Q1	$20.8M	Buy	112,819 +1,341	+1%	+$248K	0.52%	70
2018 Q4	$18.5M	Buy	111,478 +13,601	+14%	+$2.36M	0.52%	68
2018 Q3	$18.9M	Hold	97,877	–	–	0.45%	101
2018 Q2	$16.6M	Buy	97,877 +21,430	+28%	+$3.32M	0.42%	111
2018 Q1	$12.5M	Buy	+76,447	New	+$12.5M	0.3%	128

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Peregrine Capital Management's VRTX Position: Q2 2021 in Review

Peregrine Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 168,790 shares — an estimated $36.3M sold.

Peregrine Capital Management first reported a position in VRTX in Q1 2018 and held it in 13 quarters. The position peaked at $39.5M in Q2 2020. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Peregrine Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Peregrine Capital Management sold 168,790 Vertex Pharmaceuticals shares in Q2 2021, an estimated $36.3M.
Peregrine Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 13 quarters.
Peregrine Capital Management's Vertex Pharmaceuticals position peaked at $39.5M in Q2 2020.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Peregrine Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.